Balloon Expandable Covered Stents. Suddenly a Crowded Space
|
|
- Norman Dalton
- 6 years ago
- Views:
Transcription
1 Novel Balloon Expandable Covered Stents for Aorto-iliac Occlusive Disease: New Trial Data makes for an Interesting Balloon Expandable Covered Stents Comparison in Aorto-iliac Occlusive Disease: Andrew Holden Auckland Hospital Auckland, New Zealand 3 rd December 2016 Suddenly a Crowded Space Andrew Holden Auckland, New Zealand LINC 2018
2 Disclosure Speaker name: Andrew Holden... I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other Clinical Investigator X I do not have any potential conflict of interest
3 Introduction Balloon expandable stents have been widely used to manage arterial occlusive disease, particularly in the aorta and it s proximal branches Features of BE stents include: High radial resistive force (resistant and calcified lesions) Accurate deployment Ability to post-dilate 3
4 Introduction Balloon expandable stents have been widely used to manage arterial occlusive disease, particularly in the aorta and it s proximal branches Features of BE stents include: High radial resistive force (resistant and calcified lesions) Accurate deployment Ability to post-dilate BE covered endoprosthesis offer additional proven and theoretical advantages: Prevent plaque protrusion through stent Prevent in-stent neointimal hyperplasia Decrease risk of complications stemming from distal embolization, perforation, rupture, or dissection 4
5 Introduction Until recently, only one BE covered endoprosthesis has been available Getinge ADVANTA Atrium V12
6 Introduction Until recently, only one BE covered endoprosthesis has been available Getinge ADVANTA Atrium V12 Suddenly the space has become more crowded!!! BARD Lifestream Bentley BeGraft Gore VBX
7 Introduction So how do we compare these devices? In what location and in what disease state should we consider each device?
8 Introduction So how do we compare these devices? In what location and in what disease state should we consider each device? Design features of each device that may indicate advantages and disadvantages Trial evidence supporting the use in clinical applications aorto-iliac occlusive disease
9 Introduction Three of 4 device trials had a similar primary composite endpoint composite of 30 day death +/- MI as well as 9 month CD-TLR (+/- patency) All 4 trials report primary patency at ~ 9 months* Allows comparison between devices * BeGraft primary patency 12 months)
10 Getinge ADVANTA Atrium V12 Available for many years with a known track record of performance eptfe fully encapsulated stainless steel stent Site reported results only Superior performance over uncovered BE stents in aorto-iliac occlusive disease clearly demonstrated J Vasc Surg
11 Getinge ADVANTA Atrium V12 Available for many years with a known track record of performance eptfe fully encapsulated stainless steel stent Site reported results only Superior performance over uncovered BE stents in aorto-iliac occlusive disease clearly demonstrated Advantage most obvious in severe (TASC C/D) disease J Vasc Surg 2016 TASC C/D LESIONS 11
12 icast Atrium Registry Ultrasound Study (icarus) A prospective multicentre non-randomized study evaluating Atrium V12 in common and/or external iliac arteries 152 patients in 25 centres All patients had claudication or rest pain (Rutherford 2-4) Lesion length < 110mm 12
13 icast Atrium Registry Ultrasound Study (icarus) 13
14 icast Atrium Registry Ultrasound Study (icarus) Primary composite endpoint 8.1% Significantly below the pre-determined performance metric of 16.6%* Primary patency 95.1% TLR 2.9% 14
15 Electropolished 316L stainless steel stent, dual layer eptfe Pre-mounted on non-compliant balloon, guidewire Radiopaque markers on balloon shaft indicate ends of covered stent / F 7F 8F 80cm, 135cm catheters CAUTION: Investigational Device - Limited by Federal (USA) Law to Investigational Use BPV/SGF1/1016/
16 Balloon Expandable Vascular Covered Stent in the Treatment of Iliac Artery Occlusive Disease Design Prospective, Multi-Center, Non-Randomized, Single-Arm Study Objective ITT Population Assess the safety and effectiveness of the LIFESTREAM Balloon Expandable Vascular Covered Stent for the treatment of stenoses and occlusions in the common and/or external iliac arteries 155 patients at 17 investigational sites (US, Europe, New Zealand) CAUTION: Investigational Device - Limited by Federal (USA) Law to Investigational Use BPV/SGF1/1016/
17 Baseline Characteristics ITT Group Auckland City Hospital Number of Patients Age, years Male/Female, % 69/31 81/19 Weight, kg BMI, kg/m TASC Classification [1] A 96 (61.9%) 14 (66.7%) B 42 (27.1%) 5 (23.8%) C 15 (9.7%) 2 (9.5%) D 2 (1.3%) 0 (0.0%) BPV/SGF1/1016/
18 Lesion Characteristics ITT Group Auckland City Hospital Number of Lesions Mean Lesion Length, mm Vessel, % (n) Common Iliac 73.4 (141) 65.5 (19) External Iliac 26.6 (51) 34.5 (10) Moderate/Severe Calcification, % (n) 64.5 (127) 48.3 (14) Occlusion, % (n) 10.7 (21) 6.9 (2) Pre-% Diameter Stenosis CAUTION: Investigational Device - Limited by Federal (USA) Law to Investigational Use BPV/SGF1/1016/
19 9 Month Results: Primary composite endpoint 11.6% Significantly below the pre-determined performance metric of 19.5%* Primary patency 89.1% TLR 4.3% * Derived from iliac stent published literature BPV/SGF1/1016/
20 Actual Case 66 year old male, TASC B Lesion Right leg claudication, Rutherford 3 CAUTION: Investigational Device - Limited by Federal (USA) Law to Investigational Use BPV/SGF1/1016/
21 CAUTION: Investigational Device - Limited by Federal (USA) Law to Investigational Use BPV/SGF1/1016/
22 CAUTION: Investigational Device - Limited by Federal (USA) Law to Investigational Use BPV/SGF1/1016/
23 CAUTION: Investigational Device - Limited by Federal (USA) Law to Investigational Use BPV/SGF1/1016/
24 BeGraft Peripheral Stent Graft System from Bentley Stent Material: CoCr versus Stainless steel eptfe cover at 200um thickness not attached to stent struts eptfe cover folded in at both ends
25 BeGraft Peripheral Stent Graft System Performance testing 25
26 BeGraft Peripheral Stent Graft System Performance testing radial resistive force 26
27 BeGraft Peripheral Stent Graft System Performance testing - trackability 27
28 BeGraft Peripheral Stent Graft System BeGraft Peripheral Study Prospective, non randomised multicentre study N = 70 Patients TASC Classification A 77 B 14 C 6 D 3 Mean Lesion Length 34.3mm Mean degree of Stenosis 83.2 Deloose et al. J Cardiovasc Surg 2017 May 28
29 BeGraft Peripheral Stent Graft System BeGraft Peripheral Study Prospective, non randomised multicentre study N = 70 Patients TASC Classification A 77 BPrimary Patency at months 94% CFreedom from TLR 697% D 3 Mean Lesion Length 34.3mm Mean degree of Stenosis 83.2 Deloose et al. J Cardiovasc Surg 2017 May 29
30 BeGraft Plus Peripheral Stent Graft System Newest generation of BeGraft Sandwich design consisting of 2 layers of eptfe and internal and external stents Achieves superior radial force while achieving enhanced flexibility
31 Technology & clinical benefits of GORE VIABAHN VBX Balloon Expandable Endoprosthesis FEATURES Discrete, fluoropolymer-connected stainless steel rings BENEFITS Flexibility, conformability and trackability High radial strength Minimal foreshortening Ultrathin fluoropolymer balloon cover Improved endoprosthesis retention on delivery catheter CBAS Heparin Surface on the device similar to GORE VIABAHN Endoprosthesis Thromboresistant surface 31
32 Study configurations available Stent Labeled Diameter (mm) Max Post-Dilated Stent Diameter (mm) Crimped Stent Length (mm) Introducer Sheath Size (Fr) Rated Burst Pressure (atm) , 19, 39, , 19, 39, , 19, 39, , , , All configurations available in OTW 80 and 135 cm catheter lengths 32
33 VBX FLEX Clinical Study Overview 33
34 Clinical Endpoints at Nine Months Primary composite endpoint 2.3% Primary patency 96.9% TLR 2.6% 34
35 Complex Case Example 68 year old male Bilateral thigh and calf claudication Severely atheromatous aortoiliac arteries RCIA CTO, LCIA stenosis Performed as a Live case at VIVA
36 Complex Case Example 36
37 Stent Deployment (Ends to Middle) stent graft stent graft 37
38 38
39 Stent Post-dilatation Labeled device diameter (mm) Max Endoprosthesis expanded diameter (mm)
40 Complex Case Example stent graft stent graft 40 CE Mark Pending. This device is not commercially available and will only be available on the market when the CE mark can be applied by W.L. Gore & Associates.
41 Device Comparisons ability to post-dilate Stent Labeled / Nominal Diameter (mm) VIABAHN VBX Max. Post-Dilated Stent Diameter (mm) L 16 Unique configurations 76 *Bard LifeStream Max. Post-Dilated Stent Diameter (mm) Stent Labeled / Nominal Diameter (mm) Unique configurations 38 *Maquet ADVANTA V12 Stent Labeled / Nominal Diameter (mm) Max. Post-Dilated Stent Diameter (mm) Unique configurations 34 *Bentley BeGraft Stent Labeled / Nominal Diameter (mm) Max. Post-Dilated Stent Diameter (mm) Unique 48 configurations *Information obtained from product Instructions for Use 41
42 Device Comparisons icarus Bolster BeGraft VBX Lesion length (mm) o Composite endpoint 8.1% 11.6% NR 2.3% Patency 95.1% 89.7% 94.0% 96.7% Freedom from TLR 97.2% 96.7% 97% 97.4% 42
43 Device Comparisons icarus Bolster BeGraft VBX Lesion length (mm) o Composite endpoint 8.1% 11.6% NR 2.3% Patency 95.1% 89.7% 94.0% 96.7% Freedom from TLR 97.2% 96.7% 97% 97.4% 43
44 Conclusions Balloon expandable covered stents is now a much more crowded space! Getinge Atrium V12 has the advantage of a long history of reliability and predictability with more extensive clinical data 44
45 Conclusions Balloon expandable covered stents is now a much more crowded space! Getinge Atrium V12 has the advantage of a long history of reliability and predictability with more extensive clinical data The newer BE endografts have some unique design features It is likely that all devices will perform well in relatively simple disease eg TASC A, B and C iliac occlusive disease Other issues such as clinical support and price may be relevant in deciding devices for these cases 45
46 Conclusions In complex occlusive disease (eg TASC D aorto-iliac lesions), the additional confirmability of VBX may offer improve patency 46
47 Conclusions In complex occlusive disease (eg TASC D aorto-iliac lesions), the additional confirmability of VBX may offer improve patency The additional flexibility of VBX and BeGraft may offer advantages in parallel graft applications 47
48 Novel Balloon Expandable Covered Stents for Aorto-iliac Occlusive Disease: New Trial Data makes for an Interesting Balloon Expandable Covered Stents Comparison in Aorto-iliac Occlusive Disease: Andrew Holden Auckland Hospital Auckland, New Zealand 3 rd December 2016 Suddenly a Crowded Space Andrew Holden Auckland, New Zealand LINC 2018
Expanding to every demand: The GORE VIABAHN VBX Stent Graft
Expanding to every demand: The GORE VIABAHN VBX Stent Graft GORE, VIABAHN, and designs are trademarks of W. L. Gore & Associates. 2017 W. L. Gore & Associates, Inc. Program Faculty Martin Austermann, MD
More informationMid-term outcome of CERAB for aorto-iliac occlusive disease. Michel Reijnen Rijnstate Arnhem The Netherlands
Mid-term outcome of CERAB for aorto-iliac occlusive disease Michel Reijnen Rijnstate Arnhem The Netherlands Disclosure Speaker name: Michel Reijnen I have the following potential conflicts of interest
More informationVascular V12. Covered Stent. The New Standard of Care
Vascular V12 Covered Stent The New Standard of Care Innovation Novel Thermo-Conformable Covered Stent 316L stainless steel stent completely encapsulated in a proprietary one piece eptfe film cast covering
More informationStudy of a Balloon-Expandable Covered Stent for Obstructive Lesions in the Iliac Artery
Study of a Balloon-Expandable Covered Stent for Obstructive Lesions in the Iliac Artery First Look at the 24-Month Results of the BOLSTER Trial John R. Laird, MD, on behalf of the Investigators Adventist
More informationAtrium Advanta V12. Balloon Expandable Covered Stents
Atrium Advanta V12 Balloon Expandable Covered Stents This document is intended to provide information to an international audience outside of the US. V12 is not approved or available in the US. Improving
More informationFLEXIBLE, BALOON EXPANDABLE
EARLY RESULTS OF A CLINICAL TRIAL OF FLEXIBLE, BALOON EXPANDABLE COVERED STENT GRAFT IN ILIAC OCCLUSIVE DISEASE Chris LeCroy Coastal Vascular and Interventional Pensacola, Florida Clinical Trial WL GORE
More informationRESULTS OF VIABAHN IN AORTO ILIAC OCCLUSION
RESULTS OF VIABAHN IN AORTO ILIAC OCCLUSION JORGE FERNÁNDEZ NOYA ANGIOLOGY AND VASCULAR SURGERY DEPARTMENT UNIVERSITY CLINICAL HOSPITAL SANTIAGO DE COMPOSTELA ALTERNATIVAS ENDOVASCULAR TERAPÉUTICAS TREATMENT
More informationFinally, the Control You Need to Deliver Accurate Treatment
Finally, the Control You Need to Deliver Accurate Treatment LIFESTREAM Covered Stent. has joined BD When you reach for a balloon expandable stent, you require accuracy. The LIFESTREAM Balloon Expandable
More informationLIFESTREAM TM First look at the BOLSTER 2-year follow up data
LIFESTREAM TM First look at the BOLSTER 2-year follow up data Dierk Scheinert, MD, on behalf of the Investigators Department of Angiology University Hospital Leipzig, Germany Disclosure Dierk Scheinert,
More informationEndovascular treatment of severe TASC C and D external iliac artery occlusive disease. SAINT-LEBES Bertrand Toulouse FRANCE
Endovascular treatment of severe TASC C and D external iliac artery occlusive disease SAINT-LEBES Bertrand Toulouse FRANCE Disclosure Speaker name: SAINT-LEBES I have the following potential conflicts
More informationPATIENTS WITH CLI THE THREE YEARS OUTCOME OF ENDOLUMINAL BYPASS FOR PATIENTS WITH CLI
JORGE FERNÁNDEZ NOYA ANGIOLOGY AND VASCULAR SURGERY DEPARTMENT UNIVERSITARY CLINICAL HOSPITAL SANTIAGO DE COMPOSTELA THE THREE YEARS OUTCOME OF ENDOLUMINAL BYPASS FOR Disclosure Speaker name: Jorge Fernández
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationDisclosures. Iliac Stenting: How could I mess this up? Surgery vs. Stenting: Gold Standard?
Disclosures Boston Scientific, Medical Advisory Board Endologix Corp., Consultant and trainer, AFX Aorto-Iliac Disease: Bare Metal, Covered or Stent Grafts How I Decide John S. Lane III MD, FACS Professor
More informationVIRTUS: Trial Design and Primary Endpoint Results
VIRTUS: Trial Design and Primary Endpoint Results Mahmood K. Razavi, MD St. Joseph Cardiac and Vascular Center Orange, CA, USA IMPORTANT INFORMATION: These materials are intended to describe common clinical
More informationBilateral use of the Gore IBE device for bilateral CIA aneurysms and a first interim analysis of the prospective Iceberg registry
Bilateral use of the Gore IBE device for bilateral CIA aneurysms and a first interim analysis of the prospective Iceberg registry Michel MPJ Reijnen, MD, PhD Department of Vascular Surgery, Rijnstate Hospital
More informationDrug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
More informationThe Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD
The Role of Lithotripsy in Solving the Challenges of Vascular Calcium Thomas Zeller, MD 1 1 Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: X X
More informationWhich Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA
Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA Brian DeRubertis, MD, FACS Associate Professor of Surgery UCLA Division
More informationIs there still any space left for DES in the BTK area??? (Angiolite BTK trial, 6 month Data)
Is there still any space left for DES in the BTK area??? (Angiolite BTK trial, 6 month Data) (Angiolite BTK DES, IVascular) P. Goverde MD, K. Taeymans MD, K. Lauwers MD Vascular Clinic ZNA Antwerp,Belgium
More informationOutcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
More informationEndovascular Treatment of Aortoiliac Occlusive Disease: What s in My Toolbox in Jade S. Hiramoto, MD, MAS UCSF Vascular Symposium April 20, 2018
Endovascular Treatment of Aortoiliac Occlusive Disease: What s in My Toolbox in 2018 Jade S. Hiramoto, MD, MAS UCSF Vascular Symposium April 20, 2018 Disclosures Research support and royalties, Cook Inc.
More informationTHE THE MORE MORE NATURAL APPROACH TO OPTIMAL FIT
THE THE MORE MORE NATURAL APPROACH Natural Approach TO Optimal Fit TO OPTIMAL FIT Conformability without Compromise THE STANDARD IN Conformability AND Designed for flexibility and conformability in tortuous
More informationDealing with Calcification in BTK Arteries: Is Lithoplasty the Answer?
Dealing with Calcification in BTK Arteries: Is Lithoplasty the Answer? Andrew Holden, MBChB, FRANZCR, EBIR Director of Interventional Radiology Auckland, New Zealand LINC 2017 January 25 th 2017 Disclosure
More informationCOVERA covered stent to treat stenosis in arteriovenous fistula: 6-month results from the prospective, multi-center, randomized AVeNEW study
COVERA covered stent to treat stenosis in arteriovenous fistula: 6-month results from the prospective, multi-center, randomized AVeNEW study Panagiotis Kitrou MD, MSc, PhD, EBIR Consultant Interventional
More informationChimney technique combined with aortoiliac stenting for the treatment. disease. of juxtarenal aortoiliac occlusive
Chimney technique combined with aortoiliac stenting for the treatment of juxtarenal aortoiliac occlusive disease Suwanruangsri Veera,MD Kaviros Pruesttipong,MD Department of Surgery, Maharat Nakhon Ratchasima
More informationPromise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD
Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD Associate Professor of Vascular Surgery University of New South Wales Sydney,
More informationThe results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan
The results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan COI disclosure Disclosure Speaker name: Taku Kato... I have the
More informationMy personal experience with INCRAFT in standard and challenging cases
My personal experience with INCRAFT in standard and challenging cases G Pratesi, MD Vascular Surgery University of Rome Tor Vergata giovanni.pratesi@uniroma2.it Disclosure Speaker name: Giovanni Pratesi,
More informationDisclosures. In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA
In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA Disclosures No financial disclosures. Cameron M. Akbari, MD, MBA, FACS Site Director, Vascular Surgery Medstar
More informationProven Performance Through Innovative Design *
Proven Performance Through Innovative Design * Deliver Our Next Generation AV Covered Stent Results The COVERA Vascular Covered Stent builds upon proven technologies from the category leader in AV Access.
More informationMaximizing Outcomes in a complex population with Drug-coated balloon
Maximizing Outcomes in a complex population with Drug-coated balloon March 13, 2018 Chumpol Wongwanit, MD Siriraj Hospital, Mahidol University, Bangkok, Thailand LINC Asia-Pacific 2018, Hong Kong Disclosure
More informationOCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter. Patrick Muck, MD
OCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter Patrick Muck, MD Chief, Division of Vascular Surgery Good Samaritan Hospital Cincinna
More informationAssurant Cobalt Iliac BALLOON EXPANDABLE STENT SYSTEM
Assurant Cobalt Iliac BALLOON EXPANDABLE STENT SYSTEM Innovating for life. CONFORMABILIT Y 6 F S H E AT H C O M PAT I B I L I T Y THE ASSURANT COBALT ILIAC STENT, WITH ITS UNIQUE COBALT CHROMIUM MODULAR
More informationKoen Keirse, MD RZ Tienen, Belgium
Clinical Benefits of the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection from the ENTRAP Study Koen Keirse, MD RZ Tienen, Belgium Disclosure Speaker name: Koen Keirse...
More informationGORE EXCLUDER AAA Endoprosthesis demonstrates long-term durability. Michel Reijnen Rijnstate Hospital Arnhem, The Netherlands
GORE EXCLUDER AAA Endoprosthesis demonstrates long-term durability Michel Reijnen Rijnstate Hospital Arnhem, The Netherlands Disclosure Speaker name: Michel Reijnen I have the following potential conflicts
More informationLow profile TEVAR: is it an added value? Michel Bosiers, G. Torsello Münster
Low profile TEVAR: is it an added value? Michel Bosiers, G. Torsello Münster Disclosure Speaker name:...michel Bosiers... I have the following potential conflicts of interest to report: Consulting Employment
More informationShockwave Medical Lithoplasty. Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany
Shockwave Medical Lithoplasty Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany Disclosure Speaker name: Thomas Zeller, MD I have the following potential conflicts of interest
More informationDrug-coated balloons in BTK:
Drug-coated balloons in BTK: Where do we stand and what are the open questions? Dr. Marc Bosiers LINC 2019 - Leipzig My disclosures x o I do not have any potential conflicts of interest to report o I have
More informationUpdate from Korea on the Lutonix SFA registry 12 month data
Update from Korea on the Lutonix SFA registry 12 month data Prospective, Multicenter, Post-Market Registy Assessing the Clinical Use and Safety of the Lutonix Drug Coated Balloon in Femoropopliteal Arteries
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationDurable outcomes. Proven performance.
Durable outcomes. Proven performance. GORE EXCLUDER AAA Endoprosthesis GORE EXCLUDER Iliac Branch Endoprosthesis GORE EXCLUDER AAA Endoprosthesis The most-studied* EVAR stent graft designed for durable
More informationIVUS Guided Case Review Case Performed by Frank R. Arko III, MD Charlotte, NC
IVUS Guided Case Review Case Performed by Frank R. Arko III, MD Charlotte, NC The opinions and clinical experiences presented herein are for informational purposes only. Dr. Arko is a paid consultant for
More informationVariation of stent placement for distal abdominal aorta Lesion
Variation of stent placement for distal abdominal aorta Lesion Tatsuki Doijiri M.D Department of Cardiology Yamato-Seiwa Hospital Kanagawa Japan Disclosure Speaker name: Tatsuki Doijiri... I have the following
More informationISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany
ISR-treatment The Leipzig experience with purely mechanical debulking Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich I have the following
More informationNIRxcell CoCr Coronary Stent System
cordis.com/nirxcell NIRxcell CoCr Coronary Stent System Exceptional Outcomes by Design Exceptionally low TLR rate of 5.1 % at 9 months 1 Superior Deliverability and Crossability 2 Best-in-class Conformability
More informationAccurate Vessel Sizing Drives Clinical Results. IVUS In the Periphery
Accurate Vessel Sizing Drives Clinical Results IVUS In the Periphery Discussion Iida O, et. al. Study Efficacy of Intravascular Ultrasound in Femoropopliteal Stenting for Peripheral Artery Disease With
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
More informationSFA CTO Lesion Management laser or directional atherectomy?
SFA CTO Lesion Management laser or directional atherectomy? Kevin, Chung-Ho Hsu, M.D. Setion of Peripheral Vascular Disease, Division of Cardiology, China Medical University Hospital, Taichung, Taiwan
More informationPreliminary Data from the Gore EXCLUDER Thoracoabdominal Branch Endoprosthesis Early Feasibility Study
Preliminary Data from the Gore EXCLUDER Thoracoabdominal Branch Endoprosthesis Early Feasibility Study Mark A Farber, MD Professor of Surgery and Radiology Director, UNC Aortic Network University of North
More informationAnatomical challenges in EVAR
Anatomical challenges in EVAR M.H. EL DESSOKI, MD,FRCS PROFESSOR OF VASCULAR SURGERY CAIRO UNIVERSITY Disclosure Speaker name:... I have the following potential conflicts of interest to report: Consulting
More informationAll-In-One. Iliac Branch System. PER F ORM ANC E b y d e s i g n ILIAC BRANCH ENDOPROSTHESIS
All-In-One Iliac Branch System PER F ORM ANC E b y d e s i g n ILIAC BRANCH ENDOPROSTHESIS Exclusively Designed for Use in The GORE EXCLUDER Iliac Branch designed for the iliac branch, built from the same
More informationHow do I use mechanical debulking for the treatment of arterial occlusions
How do I use mechanical debulking for the treatment of arterial occlusions Sven Bräunlich, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich
More informationIs a Stent or Scaffold Necessary in The SFA?
1 2 3 Is a Stent or Scaffold Necessary in The SFA? Stents were developed to optimize acute results after angioplasty Specifically, stents are universally accepted to manage flow limiting dissections and
More informationRole of Covered Stents and Drug Eluting Balloons In Dialysis Access
Role of Covered Stents and Drug Eluting Balloons In Dialysis Access Joseph Habib, MD, FACS Assistant Professor Department of Surgery Division of Vascular and Endovascular Surgery University of Florida
More informationIs combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?
Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial G. Torsello Münster Disclosure Speaker name: G. Torsello... I have
More informationIndications for use. Contraindications within the United States
Indications for use Indications within the United States The GORE TAG Thoracic Endoprosthesis is intended for endovascular repair of all lesions of the descending thoracic aorta, including: Isolated lesions
More informationCombine the best of both worlds
S c i e n c e B a s e d E v o l u t i o n s l e a d t o R e v o l u t i o n a r y S o l u t i o n s PIONEER CoCr STENT ON DEB Combine the best of both worlds A next step in cardiovascular treatment should
More informationChristian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide
2-Year Results Of The Tack Optimized Balloon Angioplasty (TOBA) Trial For Fem- Pop Lesions Demonstrates Safety and Efficacy Of The Tack Endovascular System In Repairing Focal Post-PTA Dissections Christian
More informationRoadsaver the paradigm shift in carotid artery treatment. G. Torsello Münster
Roadsaver the paradigm shift in carotid artery treatment G. Torsello Münster Disclosure Speaker name:...g. Torsello... I have the following potential conflicts of interest to report: Consulting Employment
More informationOr is the ivolution stent a better alternative? EVOLUTION 12-month data
Or is the ivolution stent a better alternative? EVOLUTION 12-month data Dr. Marc Bosiers LINC 2018, Leipzig Conflict of interest have the following potential conflicts of interest to report: Consulting
More informationShockwave Intravascular Lithotripsy System treatment of calcified lesions: Intravascular OCT analysis
Shockwave Intravascular Lithotripsy System treatment of calcified lesions: Intravascular OCT analysis Andrew Holden, MBChB, FRANZCR, EBIR Director of Interventional Radiology Auckland, New Zealand LINC
More informationUpdate on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria
Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee Marianne Brodmann, MD Medical University Graz Graz, Austria Critical Limb Ischemia Infrapopliteal arterial disease is a leading source
More informationDCB in my practice: How the evidence influences my strategy. Yang-Jin Park
DCB in my practice: How the evidence influences my strategy Yang-Jin Park Associate Professor Division of Vascular Surgery, Department of Surgery Samsung Medical Center Sungkyunkwan University School of
More informationCHALLENGING ILIAC ACCESSES AND THROMBOSIS PREVENTION
CHALLENGING ILIAC ACCESSES AND THROMBOSIS PREVENTION ARMANDO MANSILHA MD, PhD, FEBVS UNIVERSITY HOSPITAL - PORTO Disclosure of Interest Speaker name: ARMANDO MANSILHA I have the following potential conflicts
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report G. Biro, M. Bosiers on behalf of ZILVERPASS Study Group Disclosure Speaker
More informationCOVERA Vascular Covered Stents in the Management of Dysfunctional AV Access
COVERA Vascular Covered Stents in the Management of Dysfunctional AV Access Bart L. Dolmatch, M.D., FSIR Palo Alto Medical Foundation Mountain View, CA USA This presentation is being made on behalf of
More informationMinimizing Burden, the effect of thin strut and low Chronic Outward Force SE stents
Minimizing Burden, the effect of thin strut and low Chronic Outward Force SE stents Prof. Yong LIU The affiliated hospital of southwest medical university LINC AP 2018, Hong Kong 13-15 th March Disclosure
More informationILLUMENATE FIH Direct DCB Cohort 12-Month Results
ILLUMENATE FIH Direct DCB Cohort 12-Month Results Stephan Duda Berlin Study Investigators: H. Schröder (PI), B. Lux, F. Rücker, M. Martorana, D. Meyer, H. Hartmann, S. Duda Disclosure Speaker name: S.
More informationSurgical Bypass or. Zilver PTX. 12 months preliminary data. LINC 2016, Leipzig. Marc Bosiers, MD. Marc Bosiers Koen Deloose Joren Callaert
LINC 2016, Leipzig Surgical Bypass or A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Patrick Peeters Jürgen Verbist Wouter Van den Eynde OLV Hospital,
More informationA New EVAR Device for Infrarenal AAAs
A New EVAR Device for Infrarenal AAAs Peter Nelson, MD, MS Assistant Professor of Surgery MM0203 Rev. 01 Current U.S. EVAR Devices Anatomical Fixation Proximal Fixation Powerlink - Endologix Excluder WL
More informationAtherectomy: Jetstream and Directional. George S. Chrysant, M.D.
Atherectomy: Jetstream and Directional George S. Chrysant, M.D. Disclosures Abbott Vascular: MAB, consultant, proctor Abiomed: consultant Boston Scientific: MAB, consultant, proctor Medicines Company:
More informationOvation. Sean Lyden, MD Department Chair, Vascular Surgery Cleveland Clinic
Ovation Sean Lyden, MD Department Chair, Vascular Surgery Cleveland Clinic Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationDevice Evolution. Atherectomy: Where Do We Stand After 12 Years Since FDA Clearance. Where Do We Stand? 4/18/2015
Disclosure Statement of Financial Interest Atherectomy: Where Do We Stand After 12 Years Since FDA Clearance Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationIN.PACT AV Access IDE Study Full Baseline Data. Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators
IN.PACT AV Access IDE Study Full Baseline Data Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators Disclosures Speaker name: Robert Lookstein, MD... I have the following
More informationThe essentials for BTK procedures: wires, balloons, what else
A comprehensive approach to diabetic patient Tx The essentials for BTK procedures: wires, balloons, what else Dai-Do Do Clinical and Interventional Angiology Cardiovascular Department Disclosure Speaker
More informationLessons learned from Ch-EVAR for the treatment of. Miltos Matsagkas MD, PhD, FEBVS Professor of Vascular Surgery University of Thessaly
Lessons learned from Ch-EVAR for the treatment of pararenal AAAs Miltos Matsagkas MD, PhD, FEBVS Professor of Vascular Surgery University of Thessaly Ch-EVAR Ch-EVAR = Chimney-EVAR Placement of single
More informationBIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort
BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort Prof. Dr. Gunnar TEPE, Klinikum Rosenheim, Germany CCI on behalf of the BIOLUX P-III Investigators Disclosure
More informationRobert F. Cuff, MD FACS SHMG Vascular Surgery
Robert F. Cuff, MD FACS SHMG Vascular Surgery Objectives To become familiar with the commercially available fenestrated EVAR graft Discuss techniques to increase success Review available data to determine
More informationDCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
More informationFuture Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?
Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit? John R. Laird Adventist Heart and Vascular Institute St. Helena, CA Disclosure Speaker name: John R. Laird... I have
More informationFuture Devices of Venous Interventions
Future Devices of Venous Interventions Director of Peripheral Vascular Medicine Department of Shin Kong Wu Ho-Su Memorial Hospital, Taiwan Interventional Cardiologist Tien-Yu Wu MD Disclosure Speaker name:...
More informationTreating in-stent occlusions with the Rotarex catheter : The ROBINSON study
Treating in-stent occlusions with the Rotarex catheter : The ROBINSON study final 6-month results in 30 patients Dr. Michel Bosiers Conflict of interest have the following potential conflicts of interest
More informationKlinikum Rosenheim Department of Diagnostic and Interventional Radiology
Klinikum Rosenheim Department of Diagnostic and Interventional Radiology Is Directional Atherectomy (Silverhawk Or Turbohawk) With DEB, Better Than DEB Alone: Based On The DEFINITIVE AR RCT: 1-Year Results
More informationUniversity of Groningen. Covered stents in aortoiliac occlusive disease Grimme, Frederike. DOI: /j.ejvs /j.jvir
University of Groningen Covered stents in aortoiliac occlusive disease Grimme, Frederike DOI: 10.1016/j.ejvs.2014.08.009 10.1016/j.jvir.2015.04.007 IMPORTANT NOTE: You are advised to consult the publisher's
More informationThe Auckland Experience with the Nellix EVAS System. Andrew Holden, MBChB, FRANZCR
The Auckland Experience with the Nellix EVAS System Andrew Holden, MBChB, FRANZCR Disclosure Speaker name: Associate Professor Andrew Holden I have the following potential conflicts of interest to report:
More informationHYPOGASTRIC ARTERY PRESERVATION DURING EVAR: SURGICAL AND ENDOVASCULAR TECHNIQUES Single Centre Experience. Ilaria Ficarelli
HYPOGASTRIC ARTERY PRESERVATION DURING EVAR: SURGICAL AND ENDOVASCULAR TECHNIQUES Single Centre Experience Ilaria Ficarelli Service of Vascular Surgery Cardarelli Hospital Naples Chief: Carlo Ruotolo,
More informationNext Generation of DCB: Efficacy and tolerance of drug-coated hyper-compliant balloons (DCHCB) in peripheral arteries of swine
Next Generation of DCB: Efficacy and tolerance of drug-coated hyper-compliant balloons (DCHCB) in peripheral arteries of swine Maciej Kusmierczuk 1 ; Stephanie Bienek, PhD 1 ; Sebastian Schurmann 1 ; Antje
More informationPulsar stent technology
Pulsar stent technology Michael K. W. Lichtenberg Vascular Center Arnsberg Disclosures Speaker name: Michael Lichtenberg... I have the following potential conflicts of interest to report: X Consulting
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, PA USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, PA USA Why atherectomy? Calcification is the norm not the exception Most trials do not include heavy calcification There
More informationDISRUPT PAD. (( Data Summary )) DISRUPT PAD Data Summary SPL Rev. B 2016 Shockwave Medical Inc. All rights reserved.
DISRUPT PAD (( Data Summary )) DISRUPT PAD Data Summary SPL 60971 Rev. B 1 Summary of the key findings from the DISRUPT PAD Study 99% of femoropopliteal lesions treated were moderately or severely calcified.
More informationRobert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015
Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015 Disclosure I have nothing to disclose Randomized Controlled Studies In SFA Technology: What s The Best Tool For
More informationGuidewire Selection. Making the Most Out of My Guidewire: LINC 2016: Leipzig Interventional Course Leipzig, Germany January 26-29, 2016
Making the Most Out of My Guidewire: Guidewire Selection LINC 2016: Leipzig Interventional Course Leipzig, Germany January 26-29, 2016 Brian DeRubertis, MD, FACS Associate Professor of Surgery Division
More informationYoung-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
Young-Guk Ko, M.D., Dangas G, J Am Coll Cardiol Intv 2012;5:1071 All-cause Mortality Dangas Severance G, J Am Coll Cardiovascular Cardiol Intv Hospital, 2012;5:1071 Yonsei University Health System Aneurysm-related
More informationObesity, Scaring, Access in EVAR. Kiskinis D, Melas N, Ktenidis K. 1 st Department of Surgery Aristotle University of Thessaloniki, Greece
Obesity, Scaring, Access in EVAR Kiskinis D, Melas N, Ktenidis K. 1 st Department of Surgery Aristotle University of Thessaloniki, Greece Obesity Decreased radiolucency (visibility) Max weight load < 160
More informationLong Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA
Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA Disclosures John R. Laird Within the past 12 months, I or my spouse/partner have had a
More informationHistory of the Powerlink System Design and Clinical Results. Edward B. Diethrich Arizona Heart Hospital Phoenix, AZ
History of the Powerlink System Design and Clinical Results Edward B. Diethrich Arizona Heart Hospital Phoenix, AZ Powerlink System: Unibody-Bifurcated Design Long Main Body Low-Porosity Proprietary eptfe
More information